"No one can threaten me": MP Durai Vaiko hits back at former minister KN Nehru over remarks on his association with DMK

Tiruchirappalli, Sept. 18 -- MDMK Principal Secretary and Tiruchirappalli MP Durai Vaiko on Thursday hit back at former Tamil Nadu Minister KN Nehru over his reported remarks that he wanted to join th... Read More

Bangladesh open Asian Games hockey campaign with defeat

Dhaka, Sept. 18 -- Bangladesh held four-time champions South Korea at bay for the opening quarter before slipping to a 5-0 defeat in their first Asian Games hockey match. After a goalless first quart... Read More

Overseas Vietnamese entrepreneurs seen as bridge for Vietnam-US business ties

Washington DC, Sept. 18 -- Overseas Vietnamese entrepreneurs, with their understanding of both Vietnam and the US, can serve as a "two-way bridge", helping Vietnamese businesses access the US market w... Read More

Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More

Singapore Clinical Trial: An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY 3771249 as monotherapy or combination with other cancer treatments in participants with solid tumors harboring a KRAS G12D mutation

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and... Read More

Singapore Clinical Trial: A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation.

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asci... Read More

Singapore Clinical Trial: A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by asciminib plus blinatumomab in pediatric, adolescent, and young adult participants with relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib wit... Read More

Singapore Clinical Trial: A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy... Read More

Singapore Clinical Trial: CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitax... Read More

Singapore Clinical Trial: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Singapore, Sept. 18 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus A... Read More

• ««
• «
• 3474
• 3475
• 3476
• 3477
• 3478
• 3479
• 3480
• 3481
• 3482
• 3483
• »
• »»